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A b s t r a c t  
The current study was conceded out with a vision to enhance solubility and thereby 
dissolution rate of poorly water soluble Artemether [ARTM] and Lumefantrine [LUM] [BCS-
class IV drugs] using Lutrol F127 as carrier surfactant. ItÊs difficult to choose a single carrier 
which forms solid dispersion [SD] with both the drugs by melt method. For which number of 
polymers and combination trials were carried out and finally Lutrol F127 was selected for 
further studies. SD was prepared by melt method using different ratios of drug and Lutrol 
F127. Saturation solubility study was conducted to evaluate the effect of polymer on aqueous 
solubility of ARTM and LUM. Solid state characterization was evaluated by fourier 
transformation infrared spectroscopy, differential scanning calorimetry, x-ray diffraction study 
and scanning electron microscopy. In vitro dissolution study was performed in phosphate 
buffer at pH 7.2 [with 1% SLS] and 0.1 N HCl [with 2% Benzalkonium chloride, BKC] for 
ARTM and LUM respectively. Solid state study showed partial interaction between drug and 
Lutrol F127. In vitro dissolution rate of ARTM and LUM from SD was significantly higher 
compared to pure drug. The dissolution rate of SD prepared by melt method was found to be 
higher than that of pure drugs and their physical mixtures. Thus, SD using melt method can 
be successfully used for the improvement of the dissolution rate of ARTM and LUM. 
Keywords: Artemether, Lumefantrine, Solid dispersion, Melt method, Solubility, Dissolution 
rate 
 
Introduction 
Malaria is one of the oldest infirmities of humans and even today 
approximately 40% of worldÊs populations are at risk of this 
disease. Antimalarial drugs have played a mainstream role in 
management and control of malaria in human host [1].  For 
decades, malaria chemotherapy has been reliant mostly on 
relatively small number of chemically related drugs with lack of 
structural multiplicity. These handful of drugs have their own 
precincts, of which the acquirement and spread of parasite 
multidrug resistance has been the most damaging [2].  
Artemisinin-based combination therapy [ACT] is increasingly 
being prescribed as promising treatment. ACT is based on the 
use of two drugs with different modes of action: an artemisinin-
derivative that causes rapid and effective reduction of parasite 
biomass and gametocyte carriage and a partner drug that has a 
longer duration of action. ARTMăLUM is an ACT widely used 
nowadays and consists of a registered fixed dose combination of 
ARTM [20mg] and LUM [120mg] in tablets [3]. ARTM and LUM 
both antimalarial drugs that exhibits poor oral bioavailability, 
owing to its poor aqueous solubility. The rationale is that ARTM 
will rapidly reduce parasitemia, resulting in symptomatic relief, 
and LUM will eliminate the remaining parasites. World Health 
Organization [WHO] recommends this association as first line 
therapy for falciparum malaria in endemic areas [4]. There is 
presently no other effective alternative to prevail the ever 
increasing problem of drug resistance. It is thus essential to focus 
all efforts on the research and development of novel antimalarial 
compounds and the effective delivery thereof [5].  
SD techniques are also considered useful for improving the 
dissolution of water-insoluble drugs or controlled release of drugs. 
Some research groups have demonstrated solubility 
enhancement of ARTM by SD technique using [PVPK25, MW 
25000] and polyethylene glycol [PEG4000, MW 4000] as 
excipients [6]. Rapid disintegrating taste masked tablet was 
prepared by Punit Shah and coworkers [7].  Cyclodextrin based 
host guest system also were reported in the literature [8].  There 
are various techniques for improving the solubility of poorly water-
soluble drugs. Traditional methods for producing particles with 
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enhanced solubility include the pulverization of large drug 
particles using a ball or jet mill. Spray drying and freezing 
methods have been explored for preparing polymer-containing SD 
particles to enhance the dissolution rate of drugs [9]. The rationale 
behind the selected melt method is that, it is economic, 
environmentally friendly and avoids thermal degradation of drug, 
usage of organic solvent and sophisticated equipment. Also SD 
powders which are obtained by this method and selected 
polymers are physico-chemically stable and can be easily 
formulated [10].  
SD is one of the most promising approaches to improve the oral 
bioavailability of poorly water soluble drugs. By reducing drug 
particle size to the absolute minimum, and hence improving drug 
wettability, bioavailability may be significantly improved [11, 12].  
They are usually presented as amorphous products, mainly 
acquired by two chief methods, for example, melting and solvent 
evaporation [13]. Also SD powders which are obtained by this 
method and selected surfactant are physico-chemically stable. 
Recently, surfactants have been included to stabilize the 
formulations, thus avoiding drug recrystallization and potentiating 
their solubility [14, 15]. Here first time we have explored potential 
use of surfactant to make improved SD formulation for ARTM and 
LUM. Solubility and dissolution rate enhancement of LUM using 
melt method was not reported earlier as far our knowledge.  
Experimental 
Materials 
ARTM and LUM were obtained as a gift samples from Bajaj 
Healthcare Pvt. Ltd. Mumbai, India. Lutrol F127 was a kind gift 
from BASF Chemical Ltd., Germany. All other ingredients were of 
analytical or pharmaceutical grade. Distilled water was used 
throughout the study. Sodium hydroxide, sodium chloride, 
hydrochloric acid, potassium hydrogen phosphate of analytical 
grades procured from Sd. Fine chemicals, Mumbai.  
Preliminary solubility studies 
Saturation solubility study  
An excess quantity of ARTM and LUM was placed in 20 ml 
capacity test tubes containing 10 ml of different solutions [distilled 
water, 0.1 N HCl and phosphate buffer at pH 7.2] separately. The 
samples were sonicated for 20 min at room temperature and 
capped glass test tubes were shaken for 48 h at 37μ0.1ĈC, speed 
75 rpm using orbital shaking thermo stable incubator [Boekel 
Scientific, Germany]. The sealed glass test tubes were 
equilibrated for 48 h at 37ĈC in the incubator. The solutions in the 
test tubes were vortexed and kept for centrifugation for 20 min at 
10000 rpm. The supernatant solution was then passed through a 
Whatmann Filter Paper [Grade 1] and the amount of the drug 
dissolved was analyzed spectrophotometrically [UV-1601PC, 
Shimadzu, Japan] at 211 nm and 338.6 nm for ARTM and LUM 
respectively after suitable dilution. All solubility measurements 
were performed in triplicate. [Fig. 1 & Fig. 2]  
Phase solubility study 
Phase solubility study was performed according to the method 
described by Higuchi and Connors [16]. An excess amount of 
ARTM and LUM was placed in 20 ml test tubes containing in 10 
ml of distilled water with different concentrations of Lutrol F127 
separately. Lutrol F127 [1%, 2%, 3%, 4% and 5% w/v] was used 
as hydrophilic polymer. Test tubes were covered with cellophane 
membrane to avoid solution loss and then shaken [75 
agitations/min] in orbital shaking incubator [Boekel Scientific, 
Germany] for 48 h at 37ĈC. The solutions in the test tubes were 
vortexed and kept for centrifugation for 20 min at 10000 rpm. 5 ml 
of supernatant was withdrawn and filtered through Whatmann 
Filter Paper [Grade 1]. The filtrates were analyzed using a UVă
visible spectrophotometer at 211 nm and 338.6 after suitable 
dilution. All solubility measurements were performed in triplicate 
[Fig. 3].  
 
Gibbs-free energy [ΔGĈtr] 
The ΔGĈtr value provides information about whether the treatment 
is favorable or unfavorable for drug solubilization in an aqueous 
medium. Negative Gibbs-free energy values indicate improved 
dissolution [17, 18].The ΔGĈtr values of ARTM and LUM were 
calculated using the following equation: 
ΔGĈtr = {-2.303RTLog [S0/Ss]} 
Where S0/Ss, is the ratio of the molar solubility of ARTM and LUM 
before and after treatment with surfactant Lutrol F127. The value 
of gas constant [R] is 8.31 J Kî1molî1 and T is temperature in 
degree kelvin. 
The order of Phase solubility and ΔGĈtr of ARTM and LUM at 
different concentrations of Lutrol F127 shown in [Table 1]. 
Negative values of Gibbs free energy indicates improved 
dissolution. 
 
Stability indicating HPLC method development [19, 20]  
The assay of the SD was evaluated using high-performance liquid 
chromatography [HPLC] apparatus equipped with Binary HPLC 
pump, and 2998 Photodiode Array detector [Agilent Corporation, 
Milford, Massachusetts]. A reverse-phase C18 column [150 ï 4.6 
mm; 5 øm particles] was used. The mobile phase was composed 
of waterăacetonitrile [25:75, v/v]. Samples equivalent to 20 mg of 
ARTM were dissolved in 5 mL of methanol and appropriately 
diluted and the drug content was determined by HPLC at λ = 211 
nm [19].   
For LUM acetonitrileă0.1M ammonium acetate buffer adjusted to 
pH 4.9 [85:15%, v/v] was used as the mobile phases using same 
apparatus as in case of ARTM. Samples equivalent to 120 mg of 
LUM were dissolved in 5 mL of methanol and appropriately diluted 
and the drug content was determined by HPLC at λ = 338.5 nm 
[20].   
Both the methods developed were found to be stable for acid, 
base, oxidation, reduction, heat degradation studies. Flow rate 
and injection volume was 1 ml/min and 20ø/l for both the drugs 
respectively. Inter- and intraday coefficients of variation for ARTM 
and LUM were ª10%.  
 
Fule et al. International Journal of Drug Delivery 4 (1) 95-106 [2012] 
 
PAGE | 97 |
 
Moisture uptake and Stability studies 
A weighed amount of prepared SD  about 100 mg  were placed  in 
crucibles at accelerated condition of temperature and humidity, 40 
μ2 ĈC and 75 μ 5% RH respectively in environmental test chamber 
[Thermo lab,  INDIA,]. The changes in weight of samples were 
determined using Moisture balance MB 50C [CITIZEN, India]. 
 
Preparation of SD 
SD were prepared with ARTM: Lutrol F127 and LUM: Lutrol F127 
in 1:1, 1:2, 1:3, 1:4 and 1:5 weighed ratios by melt method  
Melt method  
The drug and surfactant were weighed and mixed together in 
mortar pestle. Then the mixture was taken in a glass beaker and 
heated on a heating mantle at particular [70ĈC and 100ĈC for 
ARTM and LUM respectively] temperature, while stirred with the 
help of glass rod to form uniform solid solution. This solid solution 
was kept at ice cooled temperature and then powdered to obtain 
SD. This material was then sifted through the sieve #60 to obtain 
fine powder. Melting of a pure drug occurs at the temperature 
when the chemical potential of the crystalline drug is equal to the 
chemical potential of the drug melt. If the melt drug is miscible 
with a polymer and dissolved in it, the chemical potential of the 
drug in the solution will be lower than that of the pure drug melt, 
and this phenomenon leads to melting point depression of drug 
crystals embedded in the polymer matrix and make it amorphous 
[21].  
Solid state characterization  
Infrared spectroscopy [IR] 
IR spectroscopy was conducted using an FTIR 
Spectrophotometer [Spectrum GX-FT-IR, Perkin Elmer, USA]. 
The spectrum was recorded in the range of 4000ă400 cmî1. The 
procedure consisted of dispersing a sample in KBr followed by 
gentle mixing. The spectrum was scanned at a resolution of 4 
cmî1 and scan speed was 4.0 scans-1.  
 
Differential scanning calorimetry [DSC] 
Differential scanning calorimeter [DSC-PYRIS-1, Perkin Elmer, 
USA] was used to study the drug polymer interactions and 
thermal behavior of drug. The experiments were performed in a 
dry nitrogen atmosphere. The samples were heated at a rate of 
10ĈC minî1 from ambient temperature to the melting point. Empty 
aluminum pan was used as a reference. 
 
X-ray diffraction [XRD] 
The crystallinity between two samples was measured using a 
Miniflex apparatus [Rigaku, Japan] with CuKđ radiation. Samples 
were held on quartz frame. Diffraction pattern were obtained at a 
voltage of 45 kV and at a current of 20mA. The slide was then 
placed vertically at 0Ĉ angle in the X-ray diffractometer so that the 
X-ray beam fell on it properly. The results were recorded over a 
range of 0ă40Ĉ [2θ] using the Cu-target X-ray tube and Xe-filled 
detector. The operating conditions were: voltage 40 kV; current 20 
mA; scanning speed 1/min; temperature of acquisition: room 
temperature; detector: scintillation counter detector and sample 
holder: non-rotating holder. 
  
Scanning electron microscopy [SEM] 
The surface characteristics of samples were studied by scanning 
electron microscopy [SEM]. Double sided carbon tape was affixed 
on aluminum stubs. The powder sample was sprinkled onto the 
tape. The aluminum stubs were placed in the vacuum chamber of 
a scanning electron microscope. The samples were observed for 
morphological characterization using a gaseous secondary 
electron detector [working pressure: 0.8 Torr, acceleration 
voltage: 30.00 kV] XL 30. Model JEOL 5400 made in japan was 
used during analysis.  
 
Dissolution rate studies 
Dissolution rate studies were performed in phosphate buffer [pH 
7.2, with 1% SLS] and 0.1 N HCl [pH-1.2 with 2% BKC] at 
37μ0.5ĈC using USP Type II rotating basket apparatus, 900 ml 
and 1000 ml medium in each dissolution vessel [ELECTROLAB, 
Mumbai, India] at 100 rpm and 75 rpm for ARTM and LUM 
respectively. Pure ARTM and LUM, all the batches of SDs and 
Physical mixtures each containing 20 mg of ARTM and 120 mg of 
LUM were subjected to dissolution. Accurately weighed quantities 
of samples were filled into hard gelatin capsule shells and were 
subjected to dissolution. At predetermined intervals of 20, 40, 60, 
120 and 180 min., 10 ml of samples were withdrawn with 
replacement of equal volume of pre-warmed medium into the 
vessel.  These samples were filtered and spectrophotometrically 
assayed for drug content at 211 nm and 338.6 nm. Each test was 
performed in triplicate [n=6] [22]. 
Results 
Solubility study 
The pH of solution had a significantly effect on the solubility of 
ARTM as well as LUM. The reason for choosing phosphate buffer 
[pH 7.2] as the dissolution medium is that ARTM has a low 
solubility in water and in acidic media. Solubility of ARTM and 
LUM in different media is given in Table 2. 
Phase solubility study 
The influence of Lutrol F127 on solubility of ARTM and LUM in 
distilled water at 37ĈC is presented in Fig. 3. The phase solubility 
diagram corresponds to ARTM-LUM type profiles. The stability 
constant for Lutrol F127 was found to be 51.73 mg mlî1. At 5% 
concentrations of Lutrol F127, the solubility of ARTM and LUM 
was increased. The enhancement in solubility might be due to the 
hydrophilic nature of surfactant and surface adsorption of drug on 
the surfactant. 
HPLC Stability studies 
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The prepared SD kept for stability studies at 37ĈC at room 
temperature and 40ĈC/70 RH [relative humidity]. Samples were 
withdrawn at 3, 6 months and analyzed for drug content. 
Percentage drug content was in the range of 99.37 μ 0.81% to 
99.15 μ 0.48% in ARTM and LUM formulations respectively. All 
determinations are mean μ SD [n = 3]. 
Results of Moisture uptake studies 
Moisture uptake study is conducted to check hygroscopic nature 
of the prepared SD. No significant change in weight was observed 
after subjecting the sample to accelerated conditions of 
temperature and humidity. The accelerated stability studies 
showed that there was no considerable change in drug content 
during study duration. Drug content was found to be almost same 
as initial 99%. 
Solid state characterization study 
FTIR 
FTIR spectra of pure ARTM indicated the presence of 
characteristic peaks of O-H stretching [3393.6 cm-1], C-H 
stretching [2934.0 cm-1], and C-O-O-C bending vibrations [1157.3 
cm-1]. C=O stretching at 1655cm-1 and C-H bending at 1373.8 cm-
1. The FTIR spectra of physical mixture of ARM- Lutrol F127 
showed similar stretching vibrations. FTIR spectra of melt SD of 
ARM-Lutrol F127 showed O-H stretching [3447.3 cm-1], C-H 
stretching [2934 cm-1], carbonyl stretching [1648 cm-1] and C-H 
bending [1344.9-1459.5 cm-1] [Fig. 4]. 
FTIR spectra of pure LUM indicated the presence of characteristic 
peaks of O-H stretching [3393.8 cm-1], C-H stretching [2951.0-
2854.9 cm-1], and C-O-O-C bending vibrations [1152.5 cm-1]. 
C=O stretching at 1652.8 cm-1 and C-H bending at 1402.5 cm-1, 
C-Cl stretching [834.9-894.4 cm-1]. The FTIR spectra of PMÊs of 
LUM-Lutrol F127 showed similar stretching vibrations in functional 
and fingerprint regions [data not shown]. FTIR spectra of melt 
SDs of LUM-Lutrol F27 showed O-H stretching [3457.8 cm-1], C-H 
stretching [2872.4 cm-1], carbonyl stretching [1653.9 cm-1] and C-
H bending [1344.4-1397.8 cm-1]. The FTIR spectra of pure Lutrol 
F127 exhibited characteristic signals at 3427 cm-1 [O-H 
stretching], at 2873 cm-1 [C-H stretching vibration] [Fig. 5].  
Overall there was no chemical interference of functional groups 
between ARTM and LUM with Lutrol F127 observed.  
Interpretation of DSC 
The DSC curves obtained for pure ARTM, SD and their 
corresponding physical mixtures are displayed [Table 3]. ARTM 
showed a sharp endotherm at 90.84 ĈC corresponding to its 
melting point. There was a noticeable reduction in endothermic 
peak height and heat of fusion, in physical mixtures and in SD as 
compared to pure ARTM [Fig. 6 to Fig. 9]. These suggest that the 
physical state of ARTM changed from crystalline to amorphous. 
LUM showed a sharp endotherm at 131.54ĈC corresponding to its 
melting point. The melting peak of LUM tends to shift to lower 
temperatures in the SD powder relates to transformation of its 
crystalline behavior into amorphous nature [Fig. 10 to Fig. 13]. It 
has been known that transforming the physical state of the drug to 
amorphous or partially amorphous state leads to a high-energy 
state and high disorder, resulting in enhanced solubility and faster 
dissolution.  
XRD 
The XRD pattern of pure ARTM, LUM and that of Lutrol F127, SD 
are obtained. The XRD scan of pure ARTM and LUM showed 
intense peaks of crystallinity. Whereas the XRD pattern of 
prepared SD exhibited a reduction in both number and intensity of 
peaks. It was observed that the plain ARTM and LUM indicating 
the decrease in crystallinity or partial amorphization of the drug in 
its SD form [Fig. 14 to Fig. 16].  
SEM  
SEM micrographs of ARTM, LUM and SDs at different 
magnifications are obtained. The pure ARTM was characterized 
by crystals of bigger size and regular shape with an apparently 
smooth surface. In SDs, ARTM and LUM crystals adhered on the 
surface of polymer. The reduced crystallinity of ARTM and LUM in 
SD was further confirmed from the results of XRD and DSC 
studies [Fig. 17 to Fig. 21]. 
In vitro dissolution study 
In vitro dissolution study of SD and physical mixture [PM] 
prepared using Lutrol F127 with drug release studies in 
phosphate buffer at pH 7.2 [with 1 % SLS] for 1 h are depicted in 
[Fig. 22 & Fig. 23]. The pure drug showed a release of 18.2% at 
the end of 1 h, while SD showed 76.54% drug release in 1 h. 
While in Fig C in vitro drug release studies in buffer at pH 1.2 
[0.1N HCl, with 2 % BKC] for 1 h are depicted as pure drug 
showed a release of 12.77 % at the end of 1 h, while SD showed 
56.51 % drug release in 1 h [Fig. 24 & Fig. 25].  The percent drug 
dissolution increased with an increase in drug to Lutrol F127 ratio. 
Physical mixtures also showed an improved dissolution rate to a 
significant extent as compared with pure ARTM. The highest 
dissolution rate was exhibited by SD of ratio1:5. The 
enhancement in the dissolution of ARTM and LUM from SD can 
be ascribed due to several factors, like lack of crystallinity, particle 
size reduction, reduction in interfacial tension between 
hydrophobic drug and dissolution medium, increased wettability 
and effective surface adsorption of drug on hydrophilic carrier [i.e. 
surface SD is formed]. Lutrol F127 [size of particle-180 um] has a 
large surface area and can absorb a large amount of drug. During 
dissolution studies, the immediate sinking of the particles was 
observed.  
The dissolution profile of ARTM/ Lutrol F127 and LUM/ Lutrol 
F127 SD showed an improved dissolution when compared with 
the pure drug. The reasons for the augmentation in drug 
dissolution could be the dispersion of drug in pores of Lutrol F127 
and increased wettability. The dissolution rate of the drug 
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increased up with increment in the quantity of surfactant. This 
might be due to the intact adsorption of the drug on Lutrol F127, 
which enhances the dissolution of the drug. Thermal behavior of 
Lutrol F127 can be responsible for the intact adsorption of the 
drug. Physical mixtures also showed an improved dissolution rate.  
Mechanism of dissolution [23] 
The dissolution kinetic studies were carried out and the best 
suited results obtained in the case of Higuchi equation model. The 
value of R2 in Higuchi model is nearer to 0.1 and thus we 
conclude that dissolution followed Higuchi order kinetics [Table 4].  
Discussion 
The phase solubility study with water and with Lutrol F127 shows 
an increase in the solubility of the drug. The values of Gibbs free 
energy [ΔGĈtr ] associated with the aqueous solubility of ARTM 
and LUM in the presence of Lutrol F127 were all negative at 
various concentrations indicating the spontaneous nature of drug 
solubilization. The values decreased with increasing surfactant 
concentration, demonstrating that the reaction became more 
favorable as the concentration of surfactant increased. All SD 
formulations with various ratios of Lutrol F127 showed higher rate 
of dissolution than ARTM and LUM pure drug, and to equivalent 
physical mixtures. The pure drug ARTM and LUM showed up to 
18% and 12%dissolution over 60 min, but its SDs prepared by 
melt method with Lutrol F127 [1:5 ratio] showed dissolution of 
more than 75% and 60% over 60 min respectively.  This 
enhancement in the dissolution rate of ARTM and LUM from drug 
carrier systems can be attributed to several aspects such as 
complete amorphization of drug, increased wettability and 
dispersibility. FTIR spectroscopy shows no interference amongst 
characteristics peaks in the spectra of drug and SD prepared, 
specifying there is no chemical or functional interaction between 
the drug and the surfactant. The DSC study indicates that the 
drug is homogenously distributed in the polymer matrix and is of 
amorphous nature in prepared SD. The XRD study reveals there 
is change in the crystallinity of pure ARTM and LUM to 
amorphous state in the SD. SEM studies reveals that the drug 
particles gets entrapped within the polymer matrix and having 
smooth morphological surface which also contributed to the 
enhancement in the permeability. 
Conclusion 
The present study demonstrated a successful and simple method 
to prepare ARTM and LUM SD to enhance its aqueous solubility 
and dissolution rate. Nature and the amount of the carrier used, 
played an important role in the enhancement of dissolution rate. 
The solid state studies showed partial interaction of both the 
drugs with polymer and the decrease in crystallinity. Lutrol F127 is 
a potential matrix carrier for the delivery of the poorly soluble 
drugs. The dissolution rate has been increased with the 
increasing the concentration of polymer Lutrol F 127.  
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Table 1- Gibbs free energy calculated values of ARTM and LUM 
Conc. 
Of 
polymer 
[% w/v] 
Concentration of 
ARTM [µg/ml] 
with Lutrol F127 
ΔG°tr [J/Kmol] 
of 
ARTM 
Concentration of 
LUM [µg/ml] with 
Lutrol F127 
ΔG°tr [J/Kmol] 
of 
LUM 
1 1.713 -762.881 1.167 -2478.33 
2 2.008 -1171.73 1.575 -3250.83 
3 2.491 -1727.55 2.363 -4295.54 
4 2.85 -2074.54 3.183 -5063.89 
5 3.2 -2372.99 3.783 -5508.8 
 
 Table 2- Solubility of ARTM and LUM in different media 
Sr. No. Medium Solubility of pure ARTM [µg/ml] Solubility of pure LUM [µg/ml] 
1. Distilled water 1.18 0.44 
2. 0.1 N HCl [pH-1.2] 1.37 1.31 
3. Phosphate buffer [pH-7.2] 2.35 0.68 
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Table 3- Interpretation of DSC showing peak height, peak area and heat of fusion 
      Drug & SD 
 
DSC 
parameters 
Lutrol F127 ARTM ARTM + Lutrol F127 PM (1:1) 
 
ARTM + 
Lutrol F127 
SD (1:1) 
LUM 
LUM + Lutrol 
F127 
SD (1:1) 
System Peak 
point °C 
57.67 90.84 88.03 72.34 131.54 123.96 
Peak height 
(mW) 
6.2290 10.9852 0.3162 0.06556 6.4543 0.8541 
Peak area 
(mJ) 
154.437 247.369 2.767 2.125 21.480 58.698 
Heat of fusion 
ΔHF (J/g) 
38.6092 61.8422 0.6917 0.5313 21.480 14.6745 
Peak Onset 53.84 89.02 86.60 67.74 127.55 118.83 
Peak Endpoint 59.98 92.37 88.60 75.17 135.76 126.15 
 
Table 4- Dissolution kinetic studies 
 
 Zero order First order Higuchi Hickson 
Crowell 
 Korsemeyer 
-Peppas 
R2 0.683          -0.905 0.981 0.623  0.9735 
Slope 0.342      -0.005 18.292 19.145  1.295 
Intercept 40.58      1.749 20.31 49.625  -0.023 
 
 
                              
                                Fig. 1                                                                                   Fig. 2  
Fig. 1 & Fig. 2- Saturation solubility of ARTM and LUM in different medium [Each point refers to mean 
± SD [n=6]] 
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Fig. 3 Phase solubility profile of ARTM and LUM [Each point refers to mean ± SD [n=6]] 
 
Fig. 4 IR of Plain ARTM, ARTM-Lutrol F127 SD [1:1] and ARTM-Lutrol F127 SD [1:5] 
 
Fig. 5 IR of Plain LUM, LUM-Lutrol F127 SD [1:1] and LUM-Lutrol F127 SD [1:5] 
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       Fig. 6 DSC of pure ARTM                                 Fig. 7 DSC of ARTM-Lutrol F127 SD [1:1] 
 
                       
Fig. 8 DSC of ARTM-Lutrol F127 PM [1:1]             Fig. 9 DSC of ARTM-Lutrol F127 SD [1:5] 
 
          
Fig. 10 DSC of pure drug LUM                                 Fig. 11 DSC of LUM-Lutrol F127 SD [1:1] 
 
 
 
 
 
        
Fig. 12 DSC of LUM-Lutrol F127 PM [1:1]             Fig. 13 DSC of LUM-Lutrol F127 SD [1:5] 
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Fig. 14 X-ray diffraction patterns of plain drug ARTM and its SD with Lutrol F127 in ratio [1:1] and [1:5] 
from bottom to top respectively  
 
Fig. 15 Shows X-ray diffraction patterns of plain drug LUM and its SD with Lutrol F127 in ratio [1:1] and 
[1:5] from bottom to top respectively 
 
Fig. 16 Shows X-ray diffraction patterns of polymer Lutrol F127 
 
          
Fig. 17 SEM image of Pure ARTM               Fig. 18 SEM image of ARTM-Lutrol F127 SD [1:5]  
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          Fig. 19 SEM image of Pure LUM       Fig. 20 SEM image of LUM-Lutrol F127 SD [1:5]  
 
Fig. 21 SEM image of surfactant Lutrol F127 
 
 
 
Fig. 22 Comparative Dissolution profile of ARTM-Lutrol F127 SD formulation and pure drug ARTM [Each point refers to 
mean ± SD [n=6]] 
 
 
 
Fig. 23 Comparative Dissolution profile of ARTM-Lutrol F127 physical mixture formulation and pure drug ARTM [Each point 
refers to mean ± SD [n=6]] 
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Fig. 24 Comparative Dissolution profile of LUM-Lutrol F127 SD formulation and pure drug LUM [Each point refers to mean ± 
SD [n=6]]  
 
Fig. 25 Comparative Dissolution profile of LUM-Lutrol F127 physical mixture formulation and pure drug LUM [Each point 
refers to mean ± SD [n=6]] 
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